Document is current
Any future updates will be listed below
-
Authors
Lu, Shun
Wang, Jie
Yu, Yan
Yu, Xinmin
Hu, Yanping
Wangjun, Liao
Li, Xingya
Liu, Yuepeng
Li, Weidong
Qu, Xiaofei
Bao, Yuanyuan
Wang, Mengzhao
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03663205 at ClinicalTrials.govDocuments that mention this clinical trial
First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial
https://doi.org/10.1007/s40487-025-00378-8
Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.
https://doi.org/10.1200/jco.2024.42.16_suppl.e14617
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
https://doi.org/10.1136/jitc-2019-000437
-
Funding
Funding for this research was provided by:
BeOne Medicines, Ltd
- License Information
-
More Information
Article History
Received: 18 June 2025
Accepted: 29 August 2025
First Online: 14 September 2025
Declarations
:
: Shun Lu reports fees from AstraZeneca, BeOne Medicines, Bristol Myers Squibb, GenomiCare Hansoh, Hengrui, Hutchison MediPharma, Menarini, Mirati Therapeutics Inc, Novartis, Pfizer, Roche, Yuhan Corporation, and ZaiLab. Xiaofei Qu was an employee of BeOne Medicines, Ltd. during the time this study was conducted and manuscript developed. Yuanyuan Bao is an employee of BeOne Medicines, Ltd. Jie Wang, Yan Yu, Xinmin Yu, Yanping Hu, Liao Wangjun, Xingya Li, Yuepeng Liu, Weidong Li, and Mengzhao Wang declare no conflicts of interest.
: RATIONALE-304 was conducted in conformance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki and its amendments, and was approved by the relevant institutional review board/independent ethics committee for each study site (Supplementary Table ). Written informed consent from each patient was obtained before study participation.
